ContraFect Corporation
CFRXQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$107
Close$
Share Statistics
| Market cap | $107.00 |
|---|---|
| Enterprise Value | $-2,859,893.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-124.97 |
| Beta | -9.21 |
| Outstanding Shares | 10,704,803 |
Return
| Return on Equity | 419.12% |
|---|---|
| Return on Assets | -264.52% |
| Return on Invested Capital | 944.78% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.09 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.89 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-22.40
Average shareholder expectationRevenue Estimate
$1.50 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ContraFect Corporation
23 employeesContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead ...